

ARTICLE

Open Access

Dual extra-retinal origins of microglia in the model of retinal microglia repopulation

Yubin Huang¹, Zhen Xu¹, Shanshan Xiong¹, Guangrong Qin², Fangfang Sun¹, Jian Yang³, Ti-Fei Yuan⁴, Lei Zhao¹, Ke Wang⁵, Yu-Xiang Liang⁶, Lin Fu⁷, Tianzhun Wu¹, Kwok-Fai So^{5,6}, Yanxia Rao³ and Bo Peng¹

Abstract

Elucidating the origin of microglia is crucial for understanding their functions and homeostasis. Previous study has indicated that Nestin-positive progenitor cells differentiate into microglia and replenish the brain after depleting most brain microglia. Microglia have also shown the capacity to repopulate the retina after eliminating all retinal microglia. However, the origin(s) of repopulated retinal microglia is/are unknown. In this study, we aim to investigate the origins of repopulated microglia in the retina. Interestingly, we find that repopulated retinal microglia are not derived from Nestin-positive progenitor cells. Instead, they have two origins: the center-emerging microglia are derived from residual microglia in the optic nerve and the periphery-emerging microglia are derived from macrophages in the ciliary body/iris. Therefore, we have for the first time identified the extra-retinal origins of microglia in the adult mammalian retina by using a model of microglial repopulation, which may shed light on the target exploration of therapeutic interventions for retinal degenerative disorders.

Introduction

Cell regeneration is relatively slow in the adult mammalian central nervous system (CNS)^{1,2}. Though new neurons, astrocytes and oligodendrocytes can be generated during adulthood, neurogenesis and gliogenesis are relatively slow in the mammalian CNS due to the complicated regulations of intrinsic properties and extracellular environments^{3–5}. Once the CNS get injured, the insulted cells cannot be repaired to the normal situation⁴. Thus, the consequences of CNS degeneration are permanent and irreversible, making it critical to understand the cell regeneration in CNS for regenerative medicine design.

Microglia are resident mononuclear phagocytes in the CNS, which play important roles in the development, homeostasis and diseases^{6–10}. In the traditional

understanding, there are no microglial progenitor cells in the CNS, and microglia maintain their population through self-renewal^{11–13}. However, this notion has been challenged by a recent study that latent Nestin-positive cells in the brain are able to differentiate into microglia and repopulate the whole brain after pharmacological depletion of most resident microglia (~99%)^{14,15}. As an important part of the CNS, the regenerative capacity is largely limited in the adult mammalian retina³. Although a few cells are sporadically regenerated in the retina^{16–19}, no massive cell regeneration had been observed. Therefore, whether microglia can regenerate in the retina is unknown. If newly formed microglia can repopulate the whole retina after elimination of retinal microglia, it would be the first time observing a robust and massive cell regeneration in the retina. Furthermore, if repopulated retinal microglia are derived from the latent progenitor cell(s) as those in the brain, it will be the first definitive evidence that uncovers the progenitor or stem cell(s) in the adult mammalian retina. More importantly, it also provides insight into a novel target of therapeutic interventions for retinal degenerative disorders.

Correspondence: Yanxia Rao (yanxiarao@connect.hku.hk) or Bo Peng (bopeng@connect.hku.hk)

¹Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China

²Shanghai Center for Bioinformation Technology, Shanghai 201203, China

Full list of author information is available at the end of the article
Yubin Huang and Zhen Xu are equally contributed to this work.

© The Author(s) 2018



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

To this end, we first investigated the origin of repopulated microglia in the retina. New microglia were found to emerge and replenish the entire retina after elimination of all the resident microglia in the retina. Intriguingly, our fate mapping results demonstrated that Nestin-positive cells were not the precursor cells of repopulated retinal microglia, different from repopulated brain microglia. In contrast, repopulated retinal microglia have two populations of distinct origins: the majority of center-emerging microglia and the minority of periphery-emerging microglia. The center-emerging microglia were solely derived from residual microglia in the optic nerve, whereas the periphery-emerging microglia were derived from macrophages in the ciliary body/iris.

Therefore, by using the microglial repopulation model, we for the first time observed a robust and massive cell regeneration in the adult mammalian retina. Furthermore, we first identified extra-retinal origins of microglia in the adult retina. Our study sheds light on the origins and maintenance of microglia in the retina.

Results

Inhibition of CSF1R by PLX5622 completely eliminate retinal microglia

CSF1R is crucial for the viability of microglia. When CSF1R is genetically knocked out or pharmacologically inhibited, brain microglia are largely depleted^{14,20,21}. Therefore, we utilized the selective CSF1R inhibitor PLX5622^{22,23} to deplete microglia in the retina. PLX5622 was formulated into a standard AIN-76A rodent diet (1200 ppm; Plexxikon). Two-month old Cx3cr1^{+/GFP} mice, in which all microglia express GFP²⁴, were fed with PLX5622 formulated diet (PLX5622 for short) for up to 21 days (Fig. 1a). Twenty-four hours after CSF1R inhibition, microglial numbers were steeply reduced in both of the outer plexiform layer (OPL) (Figs. 1b-d; by 76.16%, $n = 7$, $p < 0.001$; n represents the number of retinas) and the inner plexiform layer (IPL) (Supplementary Figs. 1a-b; by 38.53%, $n = 7$, $p < 0.001$). Retinal microglia in the OPL were completely ablated after PLX5622 administration for 7 days and thereafter (Figs. 1b-d; 100%, $n = 5-8$, $p < 0.001$). Similarly, all microglia in the IPL were eliminated at day 10 of PLX5622 treatment and thereafter (Supplementary Figs. 1a-b; 100%, $n = 8$, $p < 0.001$). Notably, PLX5622 also depleted microglia in the brain (data not shown).

To further demonstrate whether retinal microglia are indeed removed instead of losing microglial markers (e.g., Cx3cr1) in response to PLX5622, we crossed Cx3cr1-CreER mice, in which all microglia express CreER²⁵⁻³⁰, with the tdTomato reporter line Ai14³¹ to obtain Cx3cr1-CreER::Ai14 mice for fate mapping. Neonatal Cx3cr1-CreER::Ai14 mice were administered with 50 μ g tamoxifen intra-gastrically for 4 days to permanently label

microglia (Supplementary Fig. 2a-b). At 2-month old, all microglia in the retina were labeled by tdTomato ($n = 8$). After PLX5622 administration for 5 days, the tdTomato-positive cell number in the retina markedly declined (Supplementary Fig. 2c-d), demonstrating the CSF1R inhibition resulted in *bona fide* depletion of microglia. Collectively, PLX5622 rapidly eliminates all retinal microglia within 10 days.

Two distinct populations of microglia replenish the retina after withdrawal of the CSF1R inhibition

Newly formed microglia are capable of replenishing the whole brain after ablation^{14,32}. Due to the lack of progenitor/stem cells, no robust and massive cell regeneration has been observed in the adult mammalian retina¹⁶. Therefore, whether microglia can regenerate is largely unknown. To address this question, we first treated adult Cx3cr1^{+/GFP} mice with PLX5622 for 14 days to eliminate all retinal microglia. Then we replaced PLX5622 formulated diet by AIN-76A control diet (CD) (Fig. 2a). We found that repopulated microglia began to emerge in the central retina near the optic nerve head (ONH) at day 5 of recovery (Fig. 2b). Then center-emerging microglia primarily relocated in the retina in a center-to-periphery manner (Fig. 2b). Microglial cell numbers significantly increased in the OPL of the middle peripheral retina (50% eccentricity) at day 14-60 of repopulation (Figs. 2c, d; $n = 6$, $p < 0.05$ for day 14 and $p < 0.001$ for day 21 and 60), but the densities of repopulated microglia were still lower than resident microglia in naïve retinas (Fig. 2d; $n = 6$, $p < 0.001$). A similar but faster trend were observed in the IPL (Supplementary Fig. 3a-b; $n = 5-8$). By day 21 of repopulation, microglia in the IPL were recovered to the normal density (Supplementary Fig. 3a-b; $n = 6$, $p > 0.05$). In addition, BrdU incorporated microglia were detected in the retina from day 10 to day 14 of repopulation (Fig. 2e and Supplementary Fig. 3c; $n = 6-8$), indicating newly forming microglia underwent cell division (proliferation and/or differentiation).

In addition to the center-emerging microglia, a minority of repopulated microglia were observed emerging at the peripheral retina and spreading in a periphery-to-center manner. A small number of microglia sporadically appeared in the peripheral retina at day 7 of repopulation (7 out of 12 retinas) and became evident by day 10 (Fig. 2b). Out of 12 retinas, 5 were apparently demarcated by 2 populations of microglia at day 14 of repopulation (Supplementary Fig. 4a). The morphology of periphery-emerging microglia was less ramified than that of center-emerging cell (Supplementary Fig. 4b). The less ramified microglia can still be observed in the peripheral retina at day 60 of microglial repopulation (3 out of 6 retinas). These results suggest that, unlike the transient-lasting blood-borne microglia/macrophages found in the




Fig. 1 Inhibition of CSF1R by PLX5622 rapidly depletes all microglia in the retina. **a** Scheme of PLX5622 administration and time points for observation. **b** Spatial distributions of retinal microglia show that the cell numbers are reduced after PLX5622 administration. Each green dot represents a microglial cell. **c** Representative confocal images show microglial numbers are reduced in the OPL of the retina after PLX5622 administration. **d** Quantification of microglial density in the OPL of normal retinas and the retinas upon PLX5622 treatment. Green: GFP. S: superior; I: inferior; N: nasal; T: temporal; PLX5622: PLX5622 formulated diet. The data are presented as mean \pm SD; NS not significant; * p < 0.05 to D0; ** p < 0.01 to D0; *** p < 0.001 to D0. One-way ANOVA with Bonferroni's *post hoc*

diseased CNS^{33–35}, the periphery-emerging microglia in the retina are long-lasting cells in the retina. Converging evidence of distinct emerging sites, disparate distributions

and diverse morphologies suggests that center and periphery-emerging microglia have different cellular origins. In spite of the differences, both populations




Fig. 2 Repopulated microglia replenish the entire retina after removal of CSF1R inhibition. **a** Scheme of microglial repopulation and time points for examination. **b** Spatial distributions of retinal microglia show that microglia repopulate the whole retina after removal of PLX5622. Each green dot represents a microglial cell. **c** Zoom-in images of microglia in the OPL. Green: GFP; magenta: BrdU. **d** Quantification of microglial density in the OPL during microglial repopulation. The red line and pink area indicate the mean and SD of microglial density in normal retinas, respectively. NS not significant; * $p < 0.05$ to D0; ** $p < 0.01$ to D0; *** $p < 0.001$ to D0; # $p < 0.05$ to the normal retina; ## $p < 0.01$ to the normal retina; ### $p < 0.001$ to the normal retina. **e** Quantification of BrdU-positive microglia among all microglia in the OPL during repopulation. NS not significant; * $p < 0.05$ to D0; ** $p < 0.01$ to D0; *** $p < 0.001$ to D0. S: superior; I: inferior; N: nasal; T: temporal; PLX5622: PLX5622 formulated diet; CD: control diet. Arrows: BrdU + microglia. The data are presented as mean \pm SD. One-way ANOVA with Bonferroni's *post hoc*

underwent cell division in the repopulating retina (Supplementary Fig. 4b). Notably, the previous study has indicated that residual microglia in the brain could repopulate the brain through self-renewal³². In contrast, the residual retinal microglia did not contribute to microglial repopulation in the retina, since all retinal microglia were eliminated before repopulation (Figs. 1-2 and Supplementary Fig. 1-3).

Collectively, the majority of new microglia begin to emerge in the central retina and repopulate the microglia-free retina in a center-to-periphery manner, whereas a minority of new microglia initially emerge at the peripheral retina and repopulate the retina in a periphery-to-center manner. Although with different morphologies, both groups of microglia undergo cell division during repopulation.

Repopulated retinal microglia are not derived from Nestin-positive cells

The previous study has indicated that repopulated brain microglia were primarily derived from Nestin-positive progenitor cells¹⁴. We thus asked whether microglial repopulation in the retina shared the same origin. To this end, we crossed the Nestin-CreER^{T2} mice, in which Nestin-positive cells express the tamoxifen inducible recombinase CreER³⁶, with Ai14 mice for fate mapping. Adult Nestin-CreER^{T2}::Ai14 mice were administered by tamoxifen (150 mg per kilogram of body weight) for 4 days to label Nestin-positive cells (Figs. 3a, b). Since tdTomato expression is induced by the irreversible genome recombination (Fig. 3b), Nestin-positive cells and their progenies permanently express tdTomato even if the cell fate changes. We reasoned if the newly formed microglia were derived from Nestin-positive cells, they must be labeled with tdTomato (Fig. 3c; hypothesis 1). Otherwise, the repopulated microglia should be tdTomato-negative (Fig. 3c; hypothesis 2). We thus removed all retinal microglia in tamoxifen-treated mice, followed by CD administration for 14 days (Fig. 3a). Surprisingly, tdTomato was not detected in repopulated retinal microglia (Fig. 3d; $n = 10$). There is an alternative possibility that the Nestin-positive progenitor cells could be a transient cell type that only emerges in response to the inhibition of CSF1R. To label the potential transient Nestin-positive progenitor cells (if any), we administered the animals by tamoxifen during the last 4 days of PLX5622 treatment (Fig. 3e). Still, we did not observe any tdTomato-positive microglia in the repopulated retina (Fig. 3f; $n = 16$). Therefore, the fate mapping results indicate that repopulated microglia of the retina are not originated from Nestin-positive cells, which is distinct from the repopulated brain microglia.

Repopulated microglia in the retina are not derived from blood cells


Blood cells are able to differentiate into microglia in diseased retinas^{33,37}. To identify whether repopulated retinal microglia are derived from blood cells, we first examined the integrity of the blood-retina-barrier (BRB) during microglial depletion and repopulation. Evans blue is a blood-brain-barrier (BBB) and BRB impermeable dye, which enters the CNS only when BBB/BRB are disrupted³⁸. Mice of PLX5622 administered for 14 days and recovered for 7 days were intraperitoneally injected with Evans blue (2%, Sigma), respectively (Supplementary Fig. 5a). Evans blue was not detected in retinas or brains of either groups (Supplementary Fig. 5b-d; $N = 5$; N represents animal number), indicating the BRB and BBB remained intact during microglial depletion and repopulation.

Next, we examined whether blood cells gave rise to repopulated microglia by parabiosis as we previously described³³. A beta-actin-GFP mouse, in which all cells are labeled by GFP³⁹, was subcutaneously connected with a C57BL/6J wild-type (WT) mouse (Supplementary Fig. 5e). The blood cells exchanged between the parabionts. 14 days after the surgery, about half of blood cells in parabiotic WT mice were GFP-positive (Supplementary Fig. 5f-g; $N = 5$). Then we completely ablated retinal microglia of the WT-Cx3cr1^{+/GFP} parabionts by 14-day PLX5622 administration, followed by CD treatment for 21 days to allow microglial repopulation (Supplementary Fig. 5e). If blood cells were capable of giving rise to retinal microglia, GFP-positive microglia should be observed in repopulating retinas of WT parabiotic mice³³. In contrast, we did not find GFP-positive microglia in all parabiotic WT retinas (Supplementary Fig. 5h-i; $n = 14$). Therefore, our data demonstrate that repopulated microglia are not derived from blood cells.

Center-emerging repopulated microglia are derived from residual microglia in the optic nerve


Although retinal microglia were completely eliminated after 10 days of PLX5622 administration, some microglia in the optic nerve still survived after the CSF1R inhibition for up to 21 days (Supplementary Fig. 6; $n = 8$). Therefore, we hypothesized that surviving microglia in the optic nerve might migrate to the retina through the ONH, thus explaining the phenomenon of the center-emerging microglia.

To test this hypothesis, we first asked whether repopulated microglia were derived from residual microglia. We utilized Cx3cr1-CreER::Ai14 mice for fate mapping, in which all microglial cells are labeled after tamoxifen induction²⁵⁻²⁷. We administered tamoxifen in the



neonatal mice (Fig. 4a). In the 2-month old mice, all microglia in the retina and optic nerve are labeled by tdTomato (Figs. 4e,g and Supplementary Fig. 6; $n = 8$). We did not find any tdTomato-positive non-microglial cells in the retina or optic nerve (data not shown). Therefore, tdTomato were exclusively expressed in all microglial cells, consistent with previous studies^{26,40}. We then depleted all retinal microglia by PLX5622 for 14 days, followed by CD recovery for 14 days (Fig. 4a). If repopulated microglia are labeled by tdTomato, they must


be derived from residual microglia (Fig. 4c; hypothesis 1). Otherwise, repopulated microglia are derived from other cells (Fig. 4c; hypothesis 2). We found that all repopulated microglia in the central and middle peripheral retina (center-emerging microglia) were tdTomato-positive (Figs. 4d, f, and g; $n = 14$, 100%). The results strongly suggest that the center-emerging repopulated microglia are solely derived from residual microglia in the optic nerve. Interestingly, a lot of repopulated microglia in the peripheral retina (periphery-emerging microglia) were



tdTomato-negative (Figs. 4d, f, and g; arrows, $n = 14$, 61.04%), indicating a different origin from the center-emerging cells.

Next, we designed two experiments to investigate whether center-emerging microglia were derived from residual microglia in the optic nerve. First, we labeled microglia in the optic nerve by intra-optic nerve injection of 4-hydroxytamoxifen (4-OHT) (Fig. 5a). Some microglia in the optic nerve were labeled by tdTomato (Fig. 5b). We then applied the intra-optic nerve injection to label optic

nerve microglia at day 3 of repopulation (Fig. 5a), when there were no microglia in the retina. At day 14 of repopulation, tdTomato-positive microglia were found in the middle peripheral retina (Fig. 5b; 10 out of 10 retinas). Notably, not all optic nerve microglia were labeled with tdTomato after one single dose of tamoxifen injection. Therefore, some repopulated retinal microglia were tdTomato-negative. The results indicate that the center-emerging microglia are derived from the residual microglia in the optic nerve. Second, we cultured microglia-free




retinas from tamoxifen-administered Cx3cr1-CreER::Ai14 mice, with or without the optic nerve (Fig. 5c). Eleven days after ex vivo culture, repopulated microglia were found in the optic nerve-connected retinal explants, but not in the optic nerve-removed retinal explants (Fig. 5d; $n = 6$ and 12, respectively), indicating that residual microglia in the optic nerve contributed to center-emerging microglia. Collectively, our results by different approaches demonstrate that the center-emerging microglia are derived from the residual microglia in the optic nerve.

Periphery-emerging microglia are derived from the ciliary body/iris macrophages


In contrast to the center-emerging microglia, some repopulated microglia in the peripheral retina were


tdTomato-negative (Figs. 4d, f, and g; arrows; $n = 14$), suggesting a residual microglia-independent origin. In addition, these tdTomato-negative microglia exhibited a less ramified morphology (Figs. 4f-g), indicating they were the periphery-emerging cells. The evidence thus suggests that the periphery-emerging microglia are not derived from residual microglia. To determine the origin, we first examined the tdTomato expression pattern in macrophages of the ciliary body and iris, the affiliated tissues to the peripheral retina. In the adult Cx3cr1-CreER::Ai14 mice with neonatal tamoxifen treatment, some macrophages did not express tdTomato in the ciliary body and iris (Supplementary Fig. 7; arrow heads), probably due to the 2-month interval in the experimental procedure allowing the turnover of macrophages. We thus



hypothesized that the periphery-emerging microglia were derived from ciliary body/iris macrophages. To test this hypothesis, we designed two experiments. First, we applied the tamoxifen administration from day 1 of depletion to day 4 of repopulation to minimize the number of tdTomato-negative macrophages (Fig. 6a). At day 4 of repopulation, when there were no microglia in the peripheral retina, all macrophages in the ciliary body and iris were labeled with tdTomato (Fig. 6b; $N = 4$). We then ceased the tamoxifen administration and examined the periphery-emerging microglia several days after repopulation (Fig. 6a). Distinct from the fate mapping results of the mice with two-month turnover interval, all

periphery-emerging microglia expressed tdTomato in the mice without turnover interval (Fig. 6b; $N = 4$), indicating periphery-emerging microglia were derived from ciliary body/iris macrophages. Second, we cultured the microglia-free retinas with or without the ciliary body and iris (Fig. 6c). 11 days after ex vivo culture, new microglia appeared in the periphery of the ciliary body/iris-connected retinal explants (Fig. 6d; $n = 5$). In contrast, no microglia were found in ciliary body/iris-removed retinal explants (Fig. 6d; $n = 5$). Consequently, evidence from the genetic inducible fate mapping and ex vivo retinal explant culture indicates that the periphery-emerging microglia are derived from the ciliary body/iris macrophages.





Taken together, by eliminating retinal microglia, we have for the first time observed a robust and massive cell regeneration in the adult mammalian retina. The repopulated retinal microglia were not derived from Nestin-positive progenitor cells or blood cells (Fig. 8). Instead, the center-emerging microglia are derived from microglia in the optic nerve and the periphery-emerging microglia are derived from macrophages in the ciliary body/iris (Fig. 8). Besides, repopulating microglia are able to undergo proliferation (Fig. 8). Repopulated microglia may play similar roles as the resident microglia in healthy and diseased retinas.

Discussion

Microglial repopulation in the retina is not contributed by Nestin-positive cells or residual retinal microglia

In the previous study of the brain, endogenous Nestin-positive progenitor cells were suggested to be able to rapidly differentiate into microglia after 99% of brain microglia were depleted¹⁴. We found that microglia were able to regenerate in the microglia-free retina. We thus initially reasoned that the repopulated retinal microglia

might share the similar origin of the brain. Unexpectedly, our fate mapping results reveal that the repopulated retinal microglia are not derived from Nestin-positive cells (Fig. 8), showing distinct cellular origins than the repopulated brain microglia. In brain repopulation study, microglia were not completely removed by pharmacological or genetic approaches¹⁴. Residual microglia also underwent proliferation during the repopulation period^{14,32}. However, different from the brain, all microglia in the retina were depleted before the microglial repopulation. Thus, repopulated microglia cannot be derived from the residual microglia in the retina.

Extra-retinal origins of retinal microglia

In the present study, we identified novel origins of retinal microglia by using the microglial repopulation model. Two distinct groups of extra-retinal cells contribute to repopulated microglia. First, the residual microglia in the optic nerve. They migrate to the retina through the optic nerve head. Then they repopulate the retina along the center-to-periphery axis (Fig. 8). This center-emerging population constitutes approximately 85% of the

repopulated microglia. Second, the macrophages from the ciliary body/iris. The ciliary body is physically connected to the peripheral retina. Based on our results, macrophages in the ciliary body can relocate to the peripheral retina and migrate towards the central retina (Fig. 8). Since the ciliary body and iris are tightly connected, macrophages in the iris are possible to migrate to the peripheral retina through the ciliary body (Fig. 8). This periphery-emerging population accounts for around 15% of the repopulated microglia, and exhibits obvious differences in morphology. The morphologies of microglia have been believed to be primarily determined by the microenvironment^{9,10,41}. Based on our observation, microglial morphologies may be also determined by intrinsic properties of the cell per se.

The ontogeny of CNS microglia and peripheral macrophages had been hotly debated for decades. For a long time, the homeostasis of microglia and macrophages had been thought to be maintained by replacement of myeloid cells in the blood⁹. However, researchers demonstrated that microglia and macrophages are autonomous and independent populations maintained by self-renewal^{9,25,42–44}. Also most of non-microglia macrophages in the brain, except for choroid plexus macrophages, established stable populations²⁹. Even under pathological conditions, the contribution of blood cells is minimal, if any^{9,33–35,45}. In this study, we for the first time uncovered the peripheral macrophage-derived microglia. Their less ramified morphology suggests distinct intrinsic properties of this population, though the functional implications are unknown.

Radial migration routes of retinal microglia

In the present study, our results also indicate novel migration routes of retinal microglia. In the diseased retina, the vertical migration of microglia has been observed. For instance, insulted photoreceptors in retinitis pigmentosa attracts microglia in the inner retina to migrate towards the outer retina^{41,46}. However, the radial migration of microglia (either centrifugally or centripetally) has not been reported in the retina, especially for the long-distance migration. In our study, the center-emerging microglia migrated along the center-to-periphery axis and the periphery-emerging microglia migrated along the periphery-to-center axis. The physiological and pathological roles of the microglial radial migration need to be further elucidated. Furthermore, what signals attract microglia to radially migrate in the retina is unknown. Microglial migration in pathological conditions is triggered by inflammatory signals. However, based on our study, inflammatory response was not detected during the microglial depletion or repopulation period. Therefore, other factors may direct the microglia to migrate. Investigating the underlying mechanism of

microglial migration in repopulation will provide new insights on understanding the regulatory principles of microglia.

Materials and methods

Ethics statements

All animal experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee (IACUC) at Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences.

Animals

C57BL/6J, beta-actin-GFP (C57BL/6-Tg(CAG-EGFP)131Osb/LeySopJ, JAX: 006567), Nestin-CreER^{T2} (C57BL/6-Tg(Nes-cre/ERT2)KEisc/J, JAX: 016261), Cx3cr1^{GFP/GFP} (B6.129P-Cx3cr1tm1Litt/J, JAX: 005582), Cx3cr1-CreER (B6.129P2(C)-Cx3cr1tm2.1(cre/ERT2)Jung/J, JAX: 020940) and Ai14 (B6.Cg-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J, JAX: 007914) mice were purchased from The Jackson Laboratories. Cx3cr1^{+GFP} knock-in mice were obtained by crossing Cx3cr1^{GFP/GFP} with C57BL/6J mice. Ai14 mice were crossed with Nestin-CreER^{T2} and Cx3cr1-CreER mice to obtain Nestin-CreER^{T2}::Ai14 and Cx3cr1-CreER::Ai14 mice, respectively. All mice were housed in the laboratory animal facility on a 12 h light and 12 h dark cycle with food and water ad libitum.

Drug administration

To deplete retinal microglia, mice were fed with PLX5622 formulated AIN-76A diet (1200 ppm, Plexxikon) at libitum. The control animals were fed with normal AIN-76A diet (Plexxikon). To systematically induce CreER dependent recombination, mice were intraperitoneally administered with tamoxifen (150 mg per kg of body weight, Sigma, C8267) dissolved in corn oil for consecutive several days³¹. For the neonatal mouse, 50 µg tamoxifen was intra-gastrically injected for consecutive 4 days as previously described^{47,48}. To locally induce CreER dependent recombination, Cx3cr1-CreER::Ai14 mice were administered with 4-hydroxytamoxifen (4-OHT, Sigma, T176) by intra-optic nerve injection (2 mm to the eye ball, 0.5 µL, 5 mg/mL in 50% DMSO).

Evans blue assay

To measure the BRB and BBB integrity during the periods of microglial depletion and repopulation, 2-month old male mice were fed by PLX5622 or CD for 14 days, and PLX5622 for 14 days followed by CD for 7 days. Mice were then intraperitoneally injected with 0.2 mL 2% Evans blue (Sigma). Six hours after injection, mice were systematically perfused by 0.9% normal saline and tissues were then harvested. Tissue homogenate was incubated with formamide (1 g tissue in 10 mL formamide, Sigma) at 55 °C for 24 h to extract Evans blue.

After that, the formamide-Evans blue mixture was centrifuged and the supernatant absorbance was measured at 610 nm by a microplate reader.

Parabiosis surgery

The parabiosis was performed following the procedures we previously described with minimal modifications³³. In brief, one female C57BL/6J mouse was co-housed with one beta-act-GFP or Cx3cr1^{+/GFP} mouse of the similar size and body weight for at least 2 weeks before the surgery to ensure the cohabitation of harmony. After deeply anesthetized with chloral hydrate (500 mg/kg, Sigma 15307), the opposite flanks of two mice were shaved and cleaned by the ethanol and Betadine solution from the elbow to the knee, before surgical incisions were made. Next, the skins were gently detached from the subcutaneous fascia to expose around 0.5 cm of free skin. After that, the adjacent elbow and knee joints were connected by the non-absorbable 3-0 suture and sutured the skins of two animals with 5-0 absorbable sutures (Ethicon, NJ). Erythromycin ointment was applied to the sutured area. Each mouse was then administered with 0.5 mL normal saline by intraperitoneally injection after procedures. Body temperatures were maintained at 37 °C by a heating pad until recovery. Meloxicam (1 mg per kg body weight, Sigma) was applied to limit infection and relieve pain. Sulfamethoxazole (2 mg/mL) and Trimethoprim (0.4 mg/mL) were added in the drinking water for 10 days to prevent potential bacterial infections. The WT/beta-actin-GFP parabiotic partners were used for blood cell analysis and the WT/Cx3cr1^{+/GFP} parabiotic partners were used to study the blood-borne origin of microglia.

Flow cytometry

The whole blood was harvested in 50 mM EDTA (Sigma) in Dulbecco's Phosphate-Buffered Saline (DPBS, HyClone, SH30028.02). The cells were incubated in ACK buffer at room temperature (Life Technologies, A10492-01) for 5 min to remove erythrocytes, followed by aspirating the supernatant and resuspending the pellets with FACS buffer (0.5% BSA and 2 mM EDTA in DPBS). After rinsed by FACS buffer for 3 changes, the cells were incubated with 7-AAD (1:80, BD Pharmingen, 559925) on ice for 10 min to label dead cells. Then the cells were analyzed by BD FACS Canto II (BD Biosciences). The blood chimera was identified by the percentage of GFP-positive blood cells in the parabiotic C57BL/6J mice. The cytometric flow data were then analyzed and plotted by FlowJo 7.6.1.

Tissue preparation

Animals were deeply anesthetized by chloral hydrate (500 mg/kg body weight). For histological experiments,

animals were perfused by 0.01 M PBS (Sigma, P4417) and 4% paraformaldehyde (PFA) (Sigma, 441244), respectively. Retinas and optic nerves were then collected and post-fixed in 4% PFA at 4 °C for 2 h. For the RNA-Seq, mouse retinas were immediately harvested in cold DPBS after deep anesthetization. Then retinas were quickly frozen in liquid nitrogen, and stored at -80 °C until further processes.

Cryosection preparation

The ciliary body and iris were dehydrated in 30% sucrose in 0.01 M PBS at 4 °C for 2 days. After embedded in optimal cutting temperature compound (OCT, Tissue-Tek), the ciliary body and iris were quickly frozen by liquid nitrogen and then stored at -80 °C before sectioning. The ciliary body and iris with regions of interest (ROIs) were sectioned by the cryostat (Leica, CM1950) at the thickness of 20 μm.

Immunohistochemistry

Whole-mount retinas and optic nerves were rinsed by PBS 10 min for 3 times, followed by 4% normal goat serum (NGS, Jackson Immuno, 005-000-121) or normal donkey serum (NDS, Jackson Immuno, 017-000-121) in 0.01 M PBS containing 0.5% Triton X-100 (Sigma-Aldrich T8787) (PBST) blocking at room temperature (RT) for 2 h. Then the samples were incubated with primary antibodies in 1% NGS or NDS in PBST at 4 °C overnight. After rinsed by PBST for 3 changes, samples were incubated with Alexa Fluor dyes conjugated secondary antibodies in 1% NGS or NDS in PBST with 4',6-diamidino-2-phenylindole (DAPI, 1:1000, Sigma-Aldrich, D9542) at RT for 2 h. After that, samples were well rinsed for 3 times before mounted with anti-fade mounting medium (Vectashield H-1000).

Primary antibodies included rabbit anti-Iba1 (1:500, Wako, 019-19741), rat anti-BrdU (1:200, Abcam, AB6326), rabbit anti-GFP (1:500, Invitrogen, A11122), chicken anti-GFP (1:200, Millipore, AB16901) and goat anti-mCherry (1:500, Biorbyt, orb11618). Secondary antibodies conjugated to Alexa Fluor 488, Alexa Fluor 568 and Alexa Fluor 647 (Molecular Probes) were 1:500 diluted.

BrdU incorporation assay

A single dose of BrdU (50 mg/kg, Invitrogen, 00-0103) was administered to the animals 24 h prior to sacrifice. Whole-mount retinas were denatured by 2 M hydrochloric acid for 20 min at RT, followed by renaturation with 0.01 M borate buffer (pH 8.2, Sigma-Aldrich 08059) at RT for 30 min before 0.01 M PBS rinse for 10 min. The immunohistochemistry was then carried out afterwards.

Retinal explant ex vivo culture

Retinas from Cx3cr1-CreER::Ai14 or Cx3cr1^{+/GFP} mice were quickly dissected in the 95% O₂ and 5% CO₂ bubbled Ames Medium (Sigma). Then the retinal explant was carefully flattened on a millicell insert (Millipore, PICM03050) in the ganglion cell-up manner. After that, the retinal explant was transferred to the six-well plate. The retinal explants were cultured in Ames Medium with 20% heat inactivated horse serum (Gibco), 16 ng/mL colony stimulating factor 1 (Sigma), 10 ng/mL IL-34 (Sigma), and 1:100 penicillin-streptomycin (Invitrogen). The retinal explants were placed in the air-medium interface and maintained at 37 °C in a humidified atmosphere with 5% CO₂. The culture medium was changed every 2 days.

Microscopy

Confocal Images were taken by solid state lasers equipped Carl Zeiss LSM 700 confocal microscope. Plan-Apochromat 20 × (0.8 NA) 40 × (1.4 NA, Oil) or 63 × (1.4 NA, Oil) objectives were used. Z-stacked focal plans were taken and then maximal projected by ZEN 2.1 (Carl Zeiss). Images were adjusted by ZEN 2.1 (Carl Zeiss) and/or ImageJ (NIH) if necessary. Images were taken in the middle peripheral retina (50% eccentricity) unless specified.

Fluorescence images of the whole retina were acquired by the Nikon TI-U microscope equipped with a motorized stage (Nikon TI-S-E). Whole retina images were merged automatically by either Nikon NIS-Elements V4.50 (Nikon) or Photoshop CS3 (Adobe). Images were adjusted by ZEN 2.1 (Carl Zeiss) and/or ImageJ (NIH) if necessary.

Data analysis

Microglial cell numbers were counted by Nikon TI-U microscope. Microglia were visualized by GFP, tdTomato or Iba1. Sampling areas were 10×, 20×, or 40× images at ROIs for each animal.

RNA sequencing

Total RNA was extracted from retinal homogenate using the TriPure Isolation Reagent (Roche) following the manufacturer's protocol. Then the RNAs were sent to BGI for 50 bp single-end sequencing by BGISEQ-500 sequencer. In Brief, Oligo (dT) magnetic beads were first used to select mRNA with polyA tail, or hybridized the rRNA with DNA probe and digested the DNA/RNA hybrid strand, followed by DNase I reaction to remove DNA probe. After the target RNA were obtained after purification, they were fragmented and reverse transcribed to the double-strand cDNA (dscDNA) by N6 random primer. Then the dscDNA was end repaired with phosphate at 5' end and stickiness "A" at 3' end, then ligated and adapted with stickiness T at 3' end to the

dscDNA. Next, two specific primers were used to amplify the ligation product. PCR products were then denatured by heat and the single strand DNA was cyclized by splint oligo and DNA ligase. After that, 50 bp single-end sequencing was performed on the prepared library by BGISEQ-500. At least 20 M clean reads of sequencing depth were obtained for each sample. All RNA-Seq raw data were uploaded in Gene Expression Omnibus (GEO ID: GSE105135).

Analysis of RNA sequencing data

RNA-Seq data were initially filtered to obtain the clean data, including removing reads with adaptors, reads with more than 10% unknown bases or low quality reads (the percentage of low quality bases is over 50% in read). Clean data were aligned to the mouse genome (MM10) using HISAT2 with default parameters⁴⁹. Htseq was used to calculate the raw counts for each sample⁵⁰. Stringtie was used to estimate the expression level of the detected genes as FPKM values⁵¹. EdgeR was used to evaluate the statistical significance of DEGs and the additive linear model was utilized to compensate the batch effect⁵².

Differentially expressed gene calculation

Sixteen groups from 65 mice were designed in this study, namely CD (control diet group), DEP2 (day 2 of microglial depletion), DEP5, DEP7, DEP10, DEP14, DEP21, REPOP3 (day 3 of microglial repopulation), REPOP5, REPOP7, REPOP10, REPOP14, REPOP21, REPOP60, LPSCD (LPS challenged normal retina), LPSREPOP (LPS challenged microglial repopulated retina). DEGs of each experimental group were detected compared to the control group. To ensure the reliable and robust analysis, genes detected in at least half of samples size and in at least one of the comparing groups were taken into consideration for DEG calculations. EdgeR was applied to detect DEGs between the compared groups⁵². DEGs were defined as genes with false discovery rate (FDR) less than 0.01 and log₂ fold change greater than 1 (up-regulation) or smaller than -1 (down-regulation).

Statistical analysis

Results were presented as mean ± standard deviation (SD). One-way analysis of variance with Bonferroni's *post hoc* was used for multiple comparisons. Independent *t*-test was performed to compare differences between two groups. The statistical significance was defined as *p* < 0.05. All statistics were performed by Prism (Graph-Pad), SPSS (IBM) or Excel (Microsoft).

Acknowledgements

This study was supported by National Key R&D Program of China (2017YFC0111202) (B.P.), National Natural Science Foundation of China (31600839) (B.P.), Shenzhen Science and Technology Research Program (JCYJ20170307171222692) (B.P.), Guangdong Innovative and Entrepreneurial

Research Team Program (2013S046) (B.P.) and Shenzhen Peacock Plan (B.P.). The authors wish to thank Prof. Wen-Biao Gan (New York University), Prof. Chong Liu (Zhejiang University) and Dr. Bin Lin (The Hong Kong Polytechnic University) for critical comments. The authors also thank Dr. Chaoran Ren, Mr. Lu Huang (Jinan University), Prof. Peigen Ren, Prof. Jian Zhang, Dr. Zhenyu Yao, Mr. Wugen Zhan, Mr. Guanglei Hu (Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences), Ms. Chi Zhang, Mr. Wei Zhao, Ms. Zhensheng Dong and Ms. Bisi Chen (BGI) for technical supports. Besides, the authors thank Dr. Paul Lin, Dr. Brian West, Parmveer Singh and Andrey Rymar (Plexikon Inc.) for kindly providing PLX5622 compound and formulated chow diet. Last but not least, the authors show their gratitude and respect to all animals sacrificed in this study.

Author details

¹Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong 518055, China. ²Shanghai Center for Bioinformation Technology, Shanghai 201203, China. ³School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. ⁴Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 201108, China. ⁵Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, Guangdong 510632, China. ⁶State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong, China. ⁷Affiliated Eye Hospital, School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang 325000, China

Author contributions

B.P. and Y.R. designed and initiated this study. B.P. convinced the data and conceptualized the research. B.P. and Y.R. supervised this study. B.P. wrote the manuscript with inputs from T.F.Y., Y.R., Y.H., Z.X., S.X., and F.S. Y.H., Z.X., S.X., F.S., Y.R., B.P., L.Z., and Y.L. performed experiments. Y.H., Z.X., Y.R., and B.P. performed most neuroanatomy experiments. S.X. maintained the transgenic animals and performed flow cytometry. Z.X., F.S., and Y.L. performed animal surgeries. G.Q. analyzed the RNA-Seq data. Y.H., S.X., K.F.S., T.W., L.F., J.Y., and B.P. performed statistical analysis of results. B.P., Y.H., Z.X., and Y.R. contributed to the interpretation of results. B.P. assembled the figures. All authors discussed results and commented on the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary Information accompanies the paper at (<https://doi.org/10.1038/s41421-018-0011-8>).

Received: 22 December 2017 Accepted: 3 January 2018

Published online: 27 February 2018

References

- Goldman, D. Müller glial cell reprogramming and retina regeneration. *Nat. Rev. Neurosci.* **15**, 431–442 (2014).
- Lepousez, G., Nissant, A. & Lledo, P.-M. Adult Neurogenesis and the Future of the Rejuvenating Brain Circuits. *Neuron* **86**, 387–401 (2015).
- Jorstad, N. L., Wilken, M. S., Grimes, W. N. et al. Stimulation of functional neuronal regeneration from Müller glia in adult mice. *Nature* **548**, 103–107 (2017).
- Anderson, M. A., Burda, J. E., Ren, Y. et al. Astrocyte scar formation aids central nervous system axon regeneration. *Nature* **532**, 195–200 (2016).
- Magnusson, J. P., Göritz, C. & Tatarishvili, J. et al. A latent neurogenic program in astrocytes regulated by Notch signaling in the mouse. *Science* **346**, 237–241 (2014).
- Kettenmann, H., Hanisch, U. K., Noda, M. & Verkhratsky, A. Physiology of microglia. *Physiol. Rev.* **91**, 461–553 (2011).
- Río Hortega, P. Microglia (1932).
- Río Hortega, P., Penfield, W. Cerebral cicatrix: the reaction of neuroglia and microglia to brain wounds (1927).
- Prinz, M. & Priller, J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. *Nat. Rev. Neurosci.* **15**, 300–312 (2014).
- Karlstetter, M. et al. Retinal microglia: just bystander or target for therapy? *Prog. Retin. Eye Res.* **45**, 30–57 (2015).
- Ajami, B., Bennett, J. L., Krieger, C., Tetzlaff, W. & Rossi, F. M. V. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. *Nat. Neurosci.* **10**, 1538–1543 (2007).
- Mildner, A., Schmidt, H. & Nitsche, M. et al. Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. *Nat. Neurosci.* **10**, 1544–1553 (2007).
- Tay, T. L., Mai, D. & Dautzenberg, J. et al. A new fate mapping system reveals context-dependent random or clonal expansion of microglia. *Nat. Neurosci.* **20**, 793–803 (2017).
- Elmore, M. R., Najafi, A. R. & Koike, M. A. et al. Colony-stimulating factor 1 receptor signaling is necessary for microglia viability, unmasking a microglia progenitor cell in the adult brain. *Neuron* **82**, 380–397 (2014).
- Hughes Ethan, G. & Bergles Dwight, E. Hidden Progenitors Replace Microglia in the Adult Brain. *Neuron* **82**, 253–255 (2014).
- Chen, M., Tian, S. & Glasgow, N. G. et al. Lgr5(+) amacrine cells possess regenerative potential in the retina of adult mice. *Aging Cell.* **14**, 635–643 (2015).
- Gualdoni, S., Baron, M. & Lakowski, J. et al. Adult ciliary epithelial cells, previously identified as retinal stem cells with potential for retinal repair, fail to differentiate into new rod photoreceptors. *Stem Cells* **28**, 1048–1059 (2010).
- Cicero, S. A., Johnson, D. & Reyntjens, S. et al. Cells previously identified as retinal stem cells are pigmented ciliary epithelial cells. *Proc. Natl. Acad. Sci. USA* **106**, 6685–6690 (2009).
- Tropepe, V., Coles, B. L. & Chiasson, B. J. et al. Retinal stem cells in the adult mammalian eye. *Science* **287**, 2032–2036 (2000).
- Erblich, B., Zhu, L., Etgen, A. M., Dobrenis, K. & Pollard, J. W. Absence of colony stimulation factor-1 receptor results in loss of microglia, disrupted brain development and olfactory deficits. *PLoS ONE.* **6**, e26317 (2011).
- Liddelstow, S. A., Guttenplan, K. A. & Clarke, L. E. et al. Neurotoxic reactive astrocytes are induced by activated microglia. *Nature* **541**, 481–487 (2017).
- Valdearcos, M., Douglass, J. D. & Robblee, M. M. et al. Microglial inflammatory signaling orchestrates the hypothalamic immune response to dietary excess and mediates obesity susceptibility. *Cell. Metab.* **26**, 185–197 e183 (2017).
- Valdearcos, M. et al. Microglia dictate the impact of saturated fat consumption on hypothalamic inflammation and neuronal function. *Cell Rep.* **9**, 2124–2138 (2014).
- Jung, S., Aliberti, J. & Graemmel, P. et al. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. *Mol. Cell. Biol.* **20**, 4106–4114 (2000).
- Yona, S., Kim, K. W. & Wolf, Y. et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. *Immunity* **38**, 79–91 (2013).
- Parkhurst, C. N., Yang, G. & Ninan, I. et al. Microglia Promote Learning-Dependent Synapse Formation through Brain-Derived Neurotrophic Factor. *Cell* **155**, 1596–1609 (2013).
- Wang, X., Zhao, L. & Zhang, J. et al. Requirement for Microglia for the Maintenance of Synaptic Function and Integrity in the Mature Retina. *J. Neurosci.* **36**, 2827–2842 (2016).
- Kierdorf, K., Erny, D. & Goldmann, T. et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. *Nat. Neurosci.* **16**, 273–280 (2013).
- Goldmann, T., Wieghofer, P. & Jordao, M. J. C. et al. Origin, fate and dynamics of macrophages at central nervous system interfaces. *Nat. Immunol.* **17**, 797 (2016).
- Goldmann, T., Wieghofer, P. & Müller, P. F. et al. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. *Nat. Neurosci.* **16**, 1618–1626 (2013).
- Madisen, L., Zwingman, T. A. & Sunkin, S. M. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. *Nat. Neurosci.* **13**, 133–140 (2010).
- Bruttger, J., Karram, K. & Wortge, S. et al. Genetic cell ablation reveals clusters of local self-renewing microglia in the mammalian central nervous system. *Immunity* **43**, 92–106 (2015).
- Yuan, T. F., Liang, Y. X., Peng, B., Lin, B. & So, K. F. Local proliferation is the main source of rod microglia after optic nerve transection. *Sci. Rep.* **5**, 10788 (2015).
- Li, T. et al. Proliferation of parenchymal microglia is the main source of microgliosis after ischaemic stroke. *Brain: a J. Neurol.* **136**, 3578–3588 (2013).

35. Ajami, B., Bennett, J. L., Krieger, C., McNagny, K. M. & Rossi, F. M. V. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. *Nat. Neurosci.* **14**, 1142–1149 (2011).
36. Lagace, D. C., Whitman, M. C. & Noonan, M. A. et al. Dynamic contribution of nestin-expressing stem cells to adult neurogenesis. *J. Neurosci.* **27**, 12623–12629 (2007).
37. Ma, W. et al. Monocyte infiltration and proliferation reestablish myeloid cell homeostasis in the mouse retina following retinal pigment epithelial cell injury. *Sci. Rep.* **7**, 8433 (2017).
38. Radu, M., Chernoff, J. An in vivo assay to test blood vessel permeability. *J. Vis. Exp.* e50062 (2013).
39. Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T. & Nishimune, Y. 'Green mice' as a source of ubiquitous green cells. *FEBS Lett.* **407**, 313–319 (1997).
40. Peng, J., Gu, N. & Zhou, L. et al. Microglia and monocytes synergistically promote the transition from acute to chronic pain after nerve injury. *Nat. Commun.* **7**, 12029 (2016).
41. Peng, B. et al. Suppression of microglial activation is neuroprotective in a mouse model of human retinitis pigmentosa. *J. Neurosci.* **34**, 8139–8150 (2014).
42. Hashimoto, D., Chow, A. & Noizat, C. et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. *Immunity* **38**, 792–804 (2013).
43. Saijo, K. & Glass, C. K. Microglial cell origin and phenotypes in health and disease. *Nat. Rev. Immunol.* **11**, 775–787 (2011).
44. Ajami, B., Bennett, J. L., Krieger, C., Tetzlaff, W. & Rossi, F. M. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. *Nat. Neurosci.* **10**, 1538–1543 (2007).
45. Miron V. E. et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. *Nat. Neurosci.* **16**, 1211–1218 (2013).
46. Marc, R. E., Jones, B. W., Watt, C. B. & Strettoi, E. Neural remodeling in retinal degeneration. *Prog. Retin. Eye Res.* **22**, 607–655 (2003).
47. Pitulescu, M. E., Schmidt, I., Benedito, R. & Adams, R. H. Inducible gene targeting in the neonatal vasculature and analysis of retinal angiogenesis in mice. *Nat. Protoc.* **5**, 1518–1534 (2010).
48. Parkhurst Christopher, N., Yang, G. & Ninan, I. et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. *Cell* **155**, 1596–1609 (2013).
49. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* **9**, 357–359 (2012).
50. Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics* **31**, 166–169 (2015).
51. Pertea, M. et al. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. *Nat. Biotechnol.* **33**, 290–295 (2015).
52. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* **26**, 139–140 (2010).